Free Trial
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

Teva Pharmaceutical Industries logo
$16.39 -0.14 (-0.85%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$16.38 -0.02 (-0.09%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Key Stats

Today's Range
$16.18
$16.43
50-Day Range
$16.13
$18.13
52-Week Range
$12.47
$22.80
Volume
9.36 million shs
Average Volume
10.27 million shs
Market Capitalization
$18.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.71
Consensus Rating
Buy

Company Overview

Teva Pharmaceutical Industries Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

TEVA MarketRank™: 

Teva Pharmaceutical Industries scored higher than 82% of companies evaluated by MarketBeat, and ranked 195th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Teva Pharmaceutical Industries has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Teva Pharmaceutical Industries has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Teva Pharmaceutical Industries' stock forecast and price target.
  • Earnings Growth

    Earnings for Teva Pharmaceutical Industries are expected to grow by 5.20% in the coming year, from $2.50 to $2.63 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Teva Pharmaceutical Industries is -14.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Teva Pharmaceutical Industries is -14.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Teva Pharmaceutical Industries has a PEG Ratio of 0.84. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Teva Pharmaceutical Industries has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Teva Pharmaceutical Industries' valuation and earnings.
  • Percentage of Shares Shorted

    3.49% of the float of Teva Pharmaceutical Industries has been sold short.
  • Short Interest Ratio / Days to Cover

    Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Teva Pharmaceutical Industries has recently decreased by 0.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    Teva Pharmaceutical Industries does not currently pay a dividend.

  • Dividend Growth

    Teva Pharmaceutical Industries does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.49% of the float of Teva Pharmaceutical Industries has been sold short.
  • Short Interest Ratio / Days to Cover

    Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Teva Pharmaceutical Industries has recently decreased by 0.32%, indicating that investor sentiment is improving.
  • News Sentiment

    Teva Pharmaceutical Industries has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Teva Pharmaceutical Industries this week, compared to 13 articles on an average week.
  • Search Interest

    Only 27 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,626.00 in company stock.

  • Percentage Held by Insiders

    Only 0.49% of the stock of Teva Pharmaceutical Industries is held by insiders.

  • Percentage Held by Institutions

    54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Teva Pharmaceutical Industries' insider trading history.
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

Teva (TEVA) Receives a Buy from Leader Capital Markets
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Headlines

TEVA Stock Analysis - Frequently Asked Questions

Teva Pharmaceutical Industries' stock was trading at $22.04 at the beginning of 2025. Since then, TEVA stock has decreased by 25.6% and is now trading at $16.39.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) released its earnings results on Wednesday, May, 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm's quarterly revenue was up 1.9% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Teva Pharmaceutical Industries include Assenagon Asset Management S.A. (0.74%), IFM Investors Pty Ltd (0.02%), Swedbank AB (0.01%) and Gateway Investment Advisers LLC (0.01%). Insiders that own company stock include Roberto Mignone, Mark Sabag, Sven Dethlefs, Eliyahu Sharon Kalif, Richard D Francis, David Matthew Stark, Eric A Hughes, Christine Fox, Amir Weiss, Matthew Shields, Eric Drape and Vikki L Conway.
View institutional ownership trends
.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD) and AT&T (T).

Company Calendar

Last Earnings
5/07/2025
Today
7/13/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:TEVA
CIK
818686
Employees
36,830
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$22.00
Potential Upside/Downside
+50.8%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
6.56
P/E Growth
0.84
Net Income
-$1.64 billion
Net Margins
-7.74%
Pretax Margin
-3.15%
Return on Equity
45.44%
Return on Assets
6.95%

Debt

Debt-to-Equity Ratio
2.59
Current Ratio
1.03
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$16.54 billion
Price / Sales
1.14
Cash Flow
$3.36 per share
Price / Cash Flow
4.88
Book Value
$4.74 per share
Price / Book
3.46

Miscellaneous

Outstanding Shares
1,146,960,000
Free Float
1,141,340,000
Market Cap
$18.80 billion
Optionable
Optionable
Beta
0.60

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:TEVA) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners